Nuo Therapeutics Inc Revenue Growth Rates (NUOT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Nuo Therapeutics Inc   (NUOT)
 

NUOT's Revenue Growth by Quarter and Year

Nuo Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NUOT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 1.30
FY 1.30





NUOT Revenue first quarter 2026 Y/Y Growth Comment
Nuo Therapeutics Inc achieved in the first quarter 2026, above Company average Revenue surge of 171.27% year on year, to $ 1.30 millions.

Looking into first quarter 2026 results within Medical Equipment & Supplies industry 7 other companies have achieved higher Revenue growth. While Nuo Therapeutics Inc ' s Revenue doubling of 171.27% ranks overall at the positon no. 149 in the first quarter 2026.


NUOT Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 156.41 % 95 % 185.71 %
3rd Quarter September - 178.38 % 60.87 % 475 %
2nd Quarter June - 94.44 % 200 % -
1st Quarter March 171.27 % 108.7 % 283.33 % -
FY   - 137.78 % 121.31 % -

Financial Statements
Nuo Therapeutics Inc 's first quarter 2026 Revenue $ 1.30 millions NUOT's Income Statement
Nuo Therapeutics Inc 's first quarter 2025 Revenue $ 0.48 millions Quarterly NUOT's Income Statement


NUOT Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -2.91 % 5.41 % -13.04 %
3rd Quarter September - 47.14 % 2.78 % 91.67 %
2nd Quarter June - 45.83 % 56.52 % 100 %
1st Quarter March 30.21 % 23.08 % 15 % -14.29 %
FY (Year on Year)   - 137.78 % 121.31 % -


Back to NUOT Growth rate Comparisons >> Back to NUOT Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #8
Healthcare Sector #50
Overall #149

Revenue Y/Y Growth Statistics
High Average Low
507.17 % 77.15 % -93.49 %
(Jun 30 2019)   (Dec 31 2021)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #8
Healthcare Sector #50
Overall #149
Revenue Y/Y Growth Statistics
High Average Low
507.17 % 77.15 % -93.49 %
(Jun 30 2019)   (Dec 31 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Nuo Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
3877.21 % 138.49 % -100 %
(Dec 31 2016)  


NUOT's I. Quarter Q/Q Revenue Comment
Nuo Therapeutics Inc achieved in the I. Quarter 2026 below company average Revenue jump of 30.21% quarter on quarter, to $ 1.30 millions.

Although the I. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the I. Quarter surge, eclipses the 23.08% growth in the I. Quarter a year ago

Within Medical Equipment & Supplies industry 22 other companies have achieved higher Revenue quarter on quarter growth. While Nuo Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 387.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #23
Healthcare Sector #86
Overall #387
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #23
Healthcare Sector #86
Overall #387
Revenue Q/Q Growth Statistics
High Average Low
3877.21 % 138.49 % -100 %
(Dec 31 2016)  


NUOT's I. Quarter Q/Q Revenue Comment
Nuo Therapeutics Inc achieved in the I. Quarter 2026 below company average Revenue jump of 30.21% quarter on quarter, to $ 1.30 millions.

I. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 23.08% in the I. Quarter a year ago.

Within Medical Equipment & Supplies industry 22 other companies have achieved higher Revenue quarter on quarter growth. While Nuo Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 387.


Nuo Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)
Cumulative Revenue 12 Months Ending $ 4.04 $ 3.22 $ 2.61 $ 1.95 $ 1.61
Y / Y Revenue Growth (TTM) 149.89 % 135.72 % 123.72 % 89.62 % 106.52 %
Year on Year Revenue Growth Overall Ranking # 117 # 87 # 69 # 45 # 41
Seqeuential Revenue Change (TTM) 25.41 % 23.22 % 33.9 % 20.77 % 18.3 %
Seq. Revenue Growth (TTM) Overall Ranking # 842 # 739 # 939 # 325 # 400


Cumulative Revenue growth Comment
Nuo Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 149.89% year on year, to $ 4 millions if the fiscal year would have ended in Mar 31 2026.
Nuo Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 64.63% and higher than 135.72% growth in Dec 31 2025.
But from twelve months ended Dec 31 2025 rise was beneth at 25.41 % from $3.22 millions achieved in the period from Dec 31 2025 to Mar 31 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at64.63%.
The momentum is even more impressive from twelve months ended Dec 31 2025 exhibited at 25.41 % increase from $3.22 millions in the period from Dec 31 2025 to Mar 31 2025.

In the Healthcare sector 46 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 87 to 117.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 55
Healthcare Sector # 47
Overall # 117

Revenue TTM Y/Y Growth Statistics
High Average Low
287.5 %
 64.63 %
-100 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 55
Sector # 176
S&P 500 # 842
Cumulative Revenue growth Comment
Nuo Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 149.89% year on year, to $ 4 millions if the fiscal year would have ended in Mar 31 2026.
Nuo Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 64.63% and higher than 135.72% growth in Dec 31 2025.
But from twelve months ended Dec 31 2025 rise was beneth at 25.41 % from $3.22 millions achieved in the period from Dec 31 2025 to Mar 31 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at64.63%.
The momentum is even more impressive from twelve months ended Dec 31 2025 exhibited at 25.41 % increase from $3.22 millions in the period from Dec 31 2025 to Mar 31 2025.

In the Healthcare sector 46 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 87 to 117.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 55
Healthcare Sector # 47
Overall # 117

Revenue TTM Y/Y Growth Statistics
High Average Low
287.5 %
64.63 %
-100 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 55
Sector # 176
S&P 500 # 842




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NUOT's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Mar 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2026
Star Equity Holdings Inc 287.35%$ 287.349 millions
Moderna Inc 260.19%$ 260.185 millions
Omniab Inc 247.30%$ 247.304 millions
Protalix Biotherapeutics inc 233.73%$ 233.729 millions
Pavmed Inc 225.00%$ 225.000 millions
Syndax Pharmaceuticals Inc 223.64%$ 223.640 millions
Catheter Precision Inc 202.10%$ 202.098 millions
Silence Therapeutics Plc197.18%$ 197.183 millions
Autolus Therapeutics Plc191.89%$ 191.895 millions
Co diagnostics Inc 190.30%$ 190.300 millions
Renovorx Inc 185.79%$ 185.787 millions
Cardio Diagnostics Holdings Inc 185.11%$ 185.106 millions
Ars Pharmaceuticals Inc 184.47%$ 184.473 millions
Tonix Pharmaceuticals Holding Corp 183.16%$ 183.162 millions
Dyadic International Inc 182.28%$ 182.275 millions
Nuo Therapeutics Inc 168.82%$ 168.820 millions
Immunitybio inc 167.64%$ 167.639 millions
Allogene Therapeutics Inc 166.67%$ 166.667 millions
Ironwood Pharmaceuticals inc 158.87%$ 158.868 millions
Urogen Pharma Ltd 155.07%$ 155.069 millions
Agios Pharmaceuticals Inc 137.75%$ 137.749 millions
Uniqure N v 127.31%$ 127.313 millions
Madrigal Pharmaceuticals Inc 126.84%$ 126.839 millions
Marker Therapeutics inc 115.32%$ 115.320 millions
Mobia Medical Inc 113.28%$ 113.284 millions
Precision Optics Corporation Inc 108.04%$ 108.043 millions
Inspiremd Inc 107.97%$ 107.972 millions
Tarsus Pharmaceuticals Inc 106.87%$ 106.873 millions
Phathom Pharmaceuticals Inc 104.43%$ 104.429 millions
Profound Medical Corp 103.62%$ 103.625 millions


About Nuo Therapeutics Inc Revenue Growth Rates (NUOT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Nuo Therapeutics Inc (CIK 1091596).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001437749-26-028053
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Nuo Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.